RxDoctor Payments Data

David Friedman, MD

Clinical Neurophysiology · Mineola, NYNPI 1295860237

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Abbott at 43.9% of the total. Reporting peaked in 2024 at $455 and has fallen 61.2% since, to $177 in 2025. That places this record below the midpoint for clinical neurophysiology clinicians in NY, where the typical reported total is $1,360.

$662in general payments, 2019–2025

Across 11 payments — averaging $60.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$291
  • Boston Scientific$147
  • UCB, Inc.$95
  • Johnson & Johnson$62
  • Vapotherm Inc$30
  • Eisai Inc.$20
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$662100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662 in reported general payments places this provider in the 30th percentile of 35 clinical neurophysiology providers in New York.

See all clinical neurophysiology providers in New York

Medicare billing

Part B allowed, 2024
$167,435
Medicare patients
567
Services billed
1,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)66$317,305
BanzelRufinamide31$250,843
BriviactBrivaracetam86$190,161
VimpatLacosamide137$174,608
FycompaPerampanel111$169,586
XcopriCenobamate79$121,232
Lamictal XrLamotrigine34$114,871
KeppraLevetiracetam26$113,779
AptiomEslicarbazepine Acetate70$95,902
LamictalLamotrigine43$90,977
OnfiClobazam21$73,612
NayzilamMidazolam35$70,992
TopamaxTopiramate26$66,806
TrileptalOxcarbazepine27$59,498
Lacosamide409$58,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$95$435,761258 claims
Eisai Inc.Banzel, Fycompa$20$420,430142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 35 clinical neurophysiology providers in New York.

Other clinical neurophysiology in Mineola

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →